Skip to main content

Table 1 Characteristics of NSCLC patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT) (N = 112)

From: Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

   N (%)
Characteristic Category non-NCT
(n = 61)
NCT
(n = 51)
Age Median 62 years 65 years
Sex Female 22 (36) 22 (43)
  Male 39 (64) 29 (57)
Tobacco history No 3 (5) 6 (12)
Yes 58 (95) 45 (88)
Smoking status Never 3 (5) 6 (12)
Former 28 (46) 14 (28)
Current 30 (49) 31 (60)
Tumor size pretreatment (CT scan) Median 4.50 cm
Tumor size posttreatment (Pathology)a Median 4.50 cm 4.10 cm
Tumor statusb T1 4 (6) 5 (10)
T2 25 (41) 23 (44)
T3 23 (38) 13 (26)
T4 9 (15) 10 (20)
Nodal statusb N0 10 (16) 7 (16)
N1 18 (29) 11 (18)
N2 33 (54) 33 (66)
AJCC stageb II 7 (12) 5 (8)
III 54 (88) 46 (92)
Histology ADC 33 (54) 31 (60)
SCC 28 (46) 20 (40)
Neoadjuvant chemotherapy Carboplatin/paclitaxel 23 (45)
Carboplatin/pemetrexed 10 (20)
Cisplatin/othersc 18 (35)
Adjuvant therapyd No 22 (36) 11 (20)
Yes 39 (64) 32 (64)
Vital status Alive 24 (39) 13 (26)
Dead 37 (61) 38 (74)
Overall survival Median 34 months 21 months
  1. ADC, adenocarcinoma; SCC, squamous cell carcinoma
  2. aby pathology report
  3. bby International Association for the Study of Lung Cancer classification system
  4. cOther chemotherapies such as gemcitabine or docetaxel
  5. dAdjuvant therapy unknown in 8 cases from NCT group